chrisvoncsefalvay/vaers-outcomes huggingface dataset:
48 hours after receiving the vaccine I started noticing soreness in the tendon in the middle of my right hand. I am concerned that the trigger finger event that happened after the 2nd dose and the 3rd dose is happening again.
This spontaneous case was reported by a consumer and describes the occurrence of AGEUSIA (loss of taste) and ANOSMIA (loss of smell) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 048A21A) for COVID-19 vaccination. No Medical History information was reported. On 10-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Mar-2021, the patient experienced AGEUSIA (loss of taste) and ANOSMIA (loss of smell). At the time of the report, AGEUSIA (loss of taste) and ANOSMIA (loss of smell) had not resolved. Concomitant product use was not provided by the reporter. No treatment information was provided.
Pt complained of dizziness and fever following vax. Pt then complained that his knees hurt, and he couldn't walk. Pt missed 3.5 days of school. Pt was taken to MD who diagnosed flu. Pt also complained of being sore all over.
how long can fever last after shingrix?; This case was reported by a consumer via interactive digital media and described the occurrence of fever in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced fever. On an unknown date, the outcome of the fever was not recovered/not resolved.   It was unknown if the reporter considered the fever to be related to Shingrix.   Additional Information: GSK Receipt Date: 09-JUN-2022 Reporter's Comment: This case was reported by a patient via interactive digital media The reporter wanted to know about how long a fever could last after the Shingrix vaccine. Additional Supportive Information: The follow up would not possible as no contact details were available.
feels like a bug bite, hasn't gone away and hasn't got any bigger, more annoying than anything else, half the time forget about it; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 08-Mar-2021 and was forwarded to Moderna on 08-Mar-2021.    This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (feels like a bug bite, hasn't gone away and hasn't got any bigger, more annoying than anything else, half the time forget about it) in a 72-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025A21A) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (feels like a bug bite, hasn't gone away and hasn't got any bigger, more annoying than anything else, half the time forget about it). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) ongoing since an unknown date for Vaccination adverse reaction, at an unspecified dose and frequency. At the time of the report, VACCINATION COMPLICATION (feels like a bug bite, hasn't gone away and hasn't got any bigger, more annoying than anything else, half the time forget about it) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported.  The patient received the first dose of the Moderna COVID-19 Vaccine on the upper left arm about 8 days prior to the day of the call and experienced something that feels like a bug bite. The patient said it is not serious and started the first day. Has not gone away and has not got any bigger.
BODY ACHES, BODY SORENESS; CHILLS; FEVER; HEADACHE; This spontaneous report received from a consumer concerned a 59 year old female. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 201A21A, expiry: UNKNOWN) dose was not reported, administered on 07-APR-2021 to left arm for prophylactic vaccination. No concomitant medications were reported. On APR-2021, the subject experienced body aches, body soreness. On APR-2021, the subject experienced chills. On APR-2021, the subject experienced fever. On APR-2021, the subject experienced headache. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the chills, fever, body aches, body soreness and headache was not reported. This report was non-serious.
Given Moderna COvVID-19 vaccine during vaccine event at facility.  EMS was called 24 hours later for patient c/o nausea, vomiting and headache.  EMS note reports they were told patient vomited black tarry fluids yesterday and again that morning.  Patient confused but has history of dementia. BP 127/88 126/88 Pulse 96-100  EMS placed patient on oxygen via nasal canula and monitor. Transported to ER.   No further info on outcome available.
Woke up next morning with severe headache. Feeling sick when standing. No appetite in 2 days.
redness, diaphoresis, early analphylaxis, given diphenhydramine and epinephrine.  observed in emergency room
Patient started experiencing pain/tingling under his right armpit and inner right arm, and on his back. This presented before a rash appeared. He saw his doctor and on 5/13/13 picked up prescriptions to treated shingles.
Information has been received from a medical assistant referring to an unspecified number of patients of unknown age and gender. The patients' medical history and concurrent conditions were not reported. Concomitant therapies included sterile diluent (manufacturer unknown). On 01-SEP-2017, the patients were vaccinated with improperly stored PROQUAD (dose, frequency and route were unknown, lot # M044720, expiration date: 07-MAY-2018, lot # N013863, expiration date: 31-OCT-2018) for prophylaxis. Administered vaccine experienced the temperature excursion of -14 Celsius degree to -10 Celsius degree (-14.2 Celsius degree) for 6 hours. There was no previous temperature excursion. Data logger was involved. No adverse effects reported. No product quality complaint (PQC) was involved. All telephone attempts on 10-OCT-2017 to obtain follow up information have been unsuccessful. Follow up information has been received from another reporter concerning a 4 year old patient. On 03-OCT-2017, the patient vaccinated with improperly stored PROQUAD (dose, frequency and route were unknown, lot # N016089, expiration date: 22-NOV-2019) for prophylaxis. This is one of several reports from the same reporter. Sender's Comments: US-009507513-1709USA002186: US-009507513-1709USA002098.
Patient received adult Pfizer dose as first dose of Pfizer vaccine series. Patient was 11 at the time of vaccination. Patient came to clinic for second dose where error was noted. Discussed with mother. Mother understood situation and mother stated she would contact pediatrician. Mother stated patient had no adverse effects after first does. Patient received pediatric Pfizer for second dose in series.
pt given vax @ 230PM-by 6PM devel a hacking, cough, eyes swollen, hives, airway closing, aching all over took DPH; 28OCT92 eyes still swollen; woke up in the noc screaming;
This report describes the occurrence of mercury poisoning in a male child of unspecified age who was vaccinated with hepatitis B vaccine for prophylaxis. This report was received as part of litigation proceedings and has not been verified by a physician or other healthcare professional. The subject's medical history, concurrent conditions, and concurrent medications were not reported. The subject received injections of hepatitis B vaccine on 8/8/94 and 9/27/94. He also received injections of diphtheria and tetanus toxoids and pertussis vaccine 9/27/94, 12/6/94, 3/3/95, 12/13/95, and 9/9/99 and Haemophilus influenzae type B conjugate vaccine 9/27/94, 12/6/94, 3/3/95, and 12/13/95. The subject's attorney alleged that as a result of the mercury in the thimerosal containing vaccinations that the subject received, he now suffers and in the future will continue to suffer, from the toxic neurological effects of mercury poisoning. The attorney further alleged that the subject has developed severe neurodevelopmental disorders with associated high mercury exposure levels as a result of the vaccinations he received, and has suffered serious permanent injury. Onset and treatment of the events were not specified. The mercury poisoning in this report, with resultant neurodevelopmental disorders is considered medically serious (OMIC).
Stomach pain and cramps.  Frequent loose bowel movements, 15-20 per day.  Excessive gas (burping) and farting constantly.  Fatigue and weak.  Lack of sleep due to having to go to rest room frequently.  Hemorrhoids pain and some bleeding due to frequent bowel movements.  Functioning daily activities difficult due to having lack of sleep and frequent rest room visits.  Symptoms still going-on as of 16 April 2021.
Nausea; Vomiting; Headache; Loss of appetite; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN5318) via an unspecified route of administration in the right arm on 24Feb2021 at 10:00 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history included diabetes, hypertension, obesity and allergy to strawberries (fruit allergy). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received other medicines (unspecified) within two weeks prior to the COVID-19 vaccine. The patient previously received zolpidem tartrate (AMBIEN) for unknown indication on an unknown date and experienced drug allergy. On 24Feb2021 at 10:30, the patient experienced nausea, vomiting, headache and loss of appetite. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event nausea, vomiting, headache and loss of appetite was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Patient felt heated, was sweating profusely, had a high fever, and had chills.
Developed a rash 2 inches below injection site which went away with Benedryl but returned yesterday which was a week after my shot and a week after the first response . The new rash is larger and in 2 spots on my left arm.
After patient received her Moderna vaccine, she was escorted by her husband  and site staff to the observation site after receiving her Moderna injection. During her 15 minute wait time she began to feel nauseous and had a witnessed fall out of her chair. Husband reported that patient had recently started a new diet and had not had a full meal yet.  EMTs were on site and assisted her immediately . 13:00 vital signs were 168/104, HR 118, oxygen saturation 99%. 13:15 158/104, HR 115, oxygen saturation 99%. EMS unit 103 arrived to transport her to Hospital at 1315.
A non serious spontaneous report of administered into eye was received from a nurse involving a four-year-old female subsequent to administration of FLUMIST. On 10-Dec-2009, the patient received FLUMIST and a portion went into her eye. There was no adverse event associated with this vaccination error, therefore treatment and reporter/sponsor causality assessments are not applicable and the event is considered to be resolved. This case is submitted in accordance with MedImmune's post-marketing commitment on accelerated reporting for the newly indicated population of 2 years to 59 months of age for FLUMIST.
PATEINT FELT SORENESS AROUND INJECTION SITE AND FATIGUE AFTER GETTING BOOSTER DOSE OF PFIZER. AT 8PM ON  03-07-2022 SHE WENT TO SLEEP BUT AWOKE AT 5AM ON 03-08-2022 WITH A MAJOR HEADACHE. HER LYMPHNODES WERE SWOLLEN UNDER HER LEFT ARM ONLY AND HAD A LOW GRADE FEVER. SHE WENT TO HOSPITAL COMPLAINING OF CHILLS AND HEADACHE.
Post first vax, no untoward effects. Approximately 4 months post second vax in mid-August, pt experienced a headache, testicular pain, and joint pain. The symptoms were treated with Celebrex, tetracycline, Ceftin and IV Rocephin, the headache has improved since Celebrex, and the joint pain is ongoing but better. Information received on 05/05/00 reports the testicular pain resolved, the headache has improved, and the joint pain is ongoing but better. Follow-up states that the pt feels the testicular pain is realted to his long history of Lyme disease. He did report decreased erectile function with decreased nocturnal erections. The pt also reported headaches. The physician reported a small inguinal hernia.
felt achy all over since it started tuesday and have been achy since then. Feels a little better 2/4/22
Pt experienced itching at the injection site that continues three weeks post vax. Pt also complained of left wrist pain. No fever and no other skin problems developed.
Sever swelling of the site of injection, red area growing down the arm. Pain, not sore but pain, hot to touch.
feeling lousy; increased shortness of breath for 2 days, higher than the baseline; occasional diarrhea; Hypotension; weakness; Fatigue; Nausea; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (feeling lousy), DYSPNOEA (increased shortness of breath for 2 days, higher than the baseline), DIARRHOEA (occasional diarrhea), HYPOTENSION (Hypotension) and ASTHENIA (weakness) in an 89-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product TREPROSTINIL SODIUM (TYVASO) inhalation gas for Primary pulmonary hypertension.    Concurrent medical conditions included Pulmonary arterial hypertension. Concomitant products included TADALAFIL and RIVAROXABAN (XARELTO) for an unknown indication.   On 06-Oct-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient started TREPROSTINIL SODIUM (TYVASO) (unknown route) at an unspecified dose. In October 2021, the patient experienced VACCINATION COMPLICATION (feeling lousy), DYSPNOEA (increased shortness of breath for 2 days, higher than the baseline), DIARRHOEA (occasional diarrhea), HYPOTENSION (Hypotension), ASTHENIA (weakness), FATIGUE (Fatigue) and NAUSEA (Nausea). At the time of the report, VACCINATION COMPLICATION (feeling lousy), DYSPNOEA (increased shortness of breath for 2 days, higher than the baseline), DIARRHOEA (occasional diarrhea), HYPOTENSION (Hypotension), ASTHENIA (weakness), FATIGUE (Fatigue) and NAUSEA (Nausea) outcome was unknown.            No Treatment medications reported
The injection was given to me as if I was a dartboard . The pain I had when I got home was so bad, and ran across back of my neck to other shoulder. I feel she injected to high up and close to shoulder ...and pain went down my left arm to hand ...also pain was radiating up back of neck... this was very concerning to me... 2-3 days with this symptom
expired dose of pre-filled syringe TYPHIM VI was administered to a patient by accident with no reported adverse event; Initial information received from on 22-Dec-2021 regarding an unsolicited valid non-serious case received from a pharmacist.  This case involves a 33 years old male patient who was administered expired dose of pre-filled syringe typhim vi  by accident with no reported adverse event while receiving vaccine TYPHOID VI POLYSACCHARIDE VACCINE [TYPHIM VI].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On 21-Dec-2021, the patient received a dose of suspect TYPHOID VI POLYSACCHARIDE VACCINE pre-filled syringe lot R2A87, expiry date: 11-Oct-2021 via intramuscular route in left shoulder site for prophylactic vaccination.  On an unknown date the patient developed a non-serious event "expired dose of pre-filled syringe typhim vi" was administered to a patient by accident with no reported adverse event (expired product administered) (unknown latency) following the administration of TYPHOID VI POLYSACCHARIDE VACCINE.  It was reported "Pharmacist states an expired dose of pre-filled syringe TYPHIM VI was administered to a patient by accident. Pharmacist states the patient is no longer planning on traveling our of the country, so they are unsure whether they should still revaccinate the patient as is looking for some guidance."  Action taken with TYPHOID VACCINE (TYPHIM VI) was not applicable.  It was not reported if the patient received a corrective treatment for the event (expired dose of pre-filled syringe TYPHIM VI was administered to a patient by accident with no reported adverse event).  At time of reporting, the outcome was Unknown for the event expired dose of pre-filled syringe typhim vi was administered to a patient by accident with no reported adverse event.   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Area observed approximately 7 cm below injection site reddened, macular rash, puffy not hard or painful to touch. Area 9x 9.5 cm in size. Denies fever or other s/s.
10/8/2021 - Patient c/o fatigue, inability to walk, decreased appetite, fever, chills, and low back pain.  Noted CK is elevated (> 12,000).  A CT scan was also done and showed colitis.  Patient is admitted with rhabdomyolysis (possibly due to the COVID vaccine of which the second dose was given on 9/20/2021) and colitis.  Note that she has a PMH of rhabdomyolysis from April 2021.  Patient was admitted to the hospital from 4/30 to 5/19/2021 with rhabdomyolysis and her first COVID vaccine was given on 4/2/2021.  Patient was given IV fluids and continued on the levofloxacin which was started on 10/5/2021 for sinusitis. 10/10/2021:  Patient became hypotensive, was given fluid boluses, transferred to the ICU and started on pressors. 10/11/2021:  C. diff pCR test came back positive and antibiotics were changed to oral vancomycin and IV metronidazole 10/12/2021:  Patient was intubated; coffee ground emesis from OGT after intubation and patient was transfused with PRBCs 10/13/2021:  Hemodynamics worsened, patient developed acute renal failure. CRRT was ordered, but never started due to instability 10/14/2021:  Patient made comfort measure and expired
pt recvd vax & broke out in a rash on arms/legs;joints fingers, wrists, elbows, knees, hips, and feet sore;rash did not itch; no induration;feet and knees remain sore
Information has been received from a licensed practical nurse concerning a 5 year old male who on 05-MAR-2003 was vaccinated subcutaneously with 0.5 ml of varicella virus vaccine live (Oka/Merck) (lot # 643586/0802M). On 22-FEB-2007 the patient developed varicella, and was recovered on 28 FEB 2007. Additional information is not expected.
(R) arm warm, mildly red, tender no red striking swollen (localized). (L) arm warm, mildly red no red striking.
After receiving vaccines, I have started experiencing preventricular contractions (PVCs) and hypertension. Neither of which were present before. As time goes on, the  PVCs are increasing both in frequency and intensity.  It has started to affect my daily life and I am now going for a full cardiac work up. Per my physician, this is the fifth report from her patients of such symptoms following the COVID vaccine.
Patient was administered PROQUAD (MMRV) vaccine that had unknowingly been in a temperature excursion too warm.
11/13/2021, post nasal drip, sore throat. My symptoms were getting worse, I had low grade fever, cough, I was taking over the counter medications: Claritin, Mucinex, Afrin & Tylenol. 11/19/2021, I went to my doctor, because I was not getting better. He said it was an Upper Respiratory. He prescribed steroid shot, and a prescription for Mucinex D and Antibiotics. I filled them 4 days later. And I slowly got better. I was completely over that on 11/26/2021. I have not had anything like this for over 20 years. I  just wasn't able to get over it. It finally felt better on 11/26/20201.
This is a spontaneous report from a contactable consumer (patient). A 53-year-old female patient (not pregnant at time of vaccination) received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 26Mar2021 at 11:15 AM (Lot number: PFR EN6204) as single dose for covid-19 immunization. Medical history included diagnosed with COVID-19. No known allergies to medications, food, or other products. Concomitant medications included azelastine and woman multi day vitamin that patient received within 2 weeks of vaccination. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient did not test for COVID-19. On 27Mar2021 at 04:00 AM, the patient experienced low grade fever, chills, aching, pain/heaviness at injection site. Lab data included COVID-19 was positive prior to vaccination. There was no treatment received for the adverse events. The outcome of events was recovered on unspecified date. This report was assessed by the patient was non-serious, no results in death, no life threatening, no caused/prolonged hospitalization, no disabling/incapacitating or no congenital anomaly/birth defect.  No follow-up attempts are needed. No further information is expected.